Abstract
Objective
To highlight the current knowledge of the effectiveness of injectable platelet rich fibrin (i-PRF) in the management of temporomandibular joint internal derangement (TMJ-ID) and temporomandibular joint osteoarthritis (TMJ-OA).
Methodology
A “Population, Intervention, Comparison, Outcome” (PICO) strategy was implemented by performing a systematic search through Cochrane databases, PubMed/MEDLINE, and Google Scholar from their commencement to November 2024. Randomized clinical trials (RCTs) addressing the management of TMJ-ID and TMJ-OA with i-PRF were included. Two reviewers independently evaluated the suitability of the RCTs, followed by data extraction.
Results
The electronic search revealed 274 articles, but only 6 studies were deemed suitable for selection, with a total of 270 subjects; 75% were females, and 25% were males. Meta-analysis revealed a significant reduction in pain levels with i-PRF compared to controls (pooled SMD = − 2.16; 95% CI = − 3.43 to − 0.89; P < 0.001). Significant improvement was also observed in maximum mouth opening (SMD = 2.46; 95% CI = 0.56 to 4.36; P = 0.02). i-PRF significantly enhanced lateral mandibular movements compared with controls (SMD = 1.35; 95% CI = 0.03 to 2.67; P = 0.048), whereas no significant difference was found for protrusive movements (SMD = 1.76; 95% CI = − 0.97 to 4.48; P = 0.11). Improvements in joint sounds and disc position were qualitatively reported in smaller subsets of studies. Substantial heterogeneity (I² = 83–93%) was observed across outcomes, reflecting variability in study design and treatment protocols.
Conclusion
Current evidence suggests that i-PRF provides improvements in TMJ pain, joint sounds, and mandibular movements for up to 12 months. However, more RCTs are needed.
Keywords: Injectable Platelet Rich Fibrin, Temporomandibular disorders, Maximum mouth opening, Visual analogue scale, Meta-analysis
Introduction
Temporomandibular disorders (TMDs) are the most common orofacial pain conditions of non-dental origin that affect the muscles and the temporomandibular joint (TMJ) [1]. TMDs can be categorized as extracapsular or intracapsular disorder. In the extracapsular disorders, it comprises masticatory muscle disorders or myogenous disorders involving myofascial pain. While in intracapsular one, it covers arthrogenous disorders involving TMJ internal derangement (TMJ-ID) where an abnormal disc-condyle relationship exists, and osteoarthritis (TMJ-OA) affecting all the TMJ structures including the articular disc, subchondral bone, ligaments, capsule, synovium, and retrodiscal tissues [2–5].
The salient signs and symptoms of intracapsular TMDs are joint clicking, pain during mandibular movements and limitation of range of motion [3–5]. Pain in intracapsular TMDs is localized in the periauricular area due to mechanical abuse of the healthy joint structures and impingement of tissues leading to inflammation of the retrodiscal tissues. Understanding the symptoms related to TMDs and their negative impact on the patient’s welfare makes the treatment of this disorder essential.
Management of patients suffering from TMDs should aim to relieve joint pain and improve dysfunction with the prevention of the disease progression. Throughout the years, treatment modalities of TMDs ranged from non-surgical approaches to surgical ones [6–12]. However, conservative as well as minimally invasive techniques, including physiotherapy, drug therapy, oral appliances, intra-articular injections, or a combination of these modalities [7, 9], should be considered as a first-line approach prior to any invasive interventions. Nevertheless, recent research supports the positive effect of certain therapies such as the injection of autologous blood or platelet concentrates (PC) in cases of TMJ-ID and TMJ-OA [13–31].
PC derived through the centrifugation of a blood sample, contains various growth factors with anti-inflammatory effects and healing enhancing properties; hence, stimulate cell proliferation and tissue repair [32–35]. The theory about PC effect is the in-situ release of autogenous growth factors which promote a revolution in regenerative medicine.
Marx et al. [34] introduced the platelet-rich plasma (PRP) as the first generation of PC. The main advantage of PRP is its fluid nature, allowing it to be used as an injectable regenerative agent for osteoarthritic joints. Several studies have documented its beneficial effect in the treatment of intracapsular TMDs. However, PRP has two main disadvantages where it requires the addition of an anticoagulant and the complex preparation procedure.
In 2000, a second generation of PC, the platelet rich fibrin (PRF), was developed by Choukroun et al. [35]. PRF is a fibrin-rich gel derived from a venous blood sample that is collected in plain tubes with no anticoagulant, then immediately centrifuged at a fixed speed for 10 min in a single step. As a result of this process, a fibrin-rich gel with aggregated platelets is formed between the red blood cells and platelet poor plasma. Nearly two decades after preparing PRF, Choukroun et al. [36] introduced a new low-speed centrifugation protocol where thrombin and liquid fibrinogen are not yet turned into fibrin resulting in a liquid PRF. This injectable PRF (i-PRF) is rich in platelets, white blood cells, and growth factors which accelerate new bone formation, cartilage repair and tissue healing. Since then, the i-PRF has been injected into joint spaces like the PRP, but with a quicker preparation procedure and longer growth factors in situ release time [36–38].
Therefore, this systematic review was conducted to investigate the RCTs available in the literature addressing the treatment outcomes of i-PRF on patients with TMJ-ID and TMJ-OA. Our focused question was “Is i-PRF effective in the management of intracapsular TMDs regarding pain relief and increased mouth opening?” In formulating our review question, we put into consideration identifying the problem “intracapsular TMDs”, intervention “i-PRF”, comparison “any other intervention,” and outcome “treatment”.
Thus, the purpose of this systematic review is to assess the efficacy of i-PRF in the management of TMJ-ID and TMD-OA. Furthermore, it highlights the preparation and injection protocols of i-PRF in the TMJ.
Materials and methods
A PICO strategy was formulated using an electronic search through Cochrane and PubMed/MEDLINE databases in addition to Google Scholar, focusing on randomized clinical trials (RCTs) investigating the management of TMDs with i-PRF. These databases were searched from their inception to November 2024.
The keywords used while searching for relevant studies included specific Medical Subject Headings (MeSH) terms including “platelet rich fibrin” AND “temporomandibular disorders” AND “pain” AND “mouth opening”. Published RCTs that answer the main study question assessing the use of i-PRF in patients suffering from TMJ-ID and TMJ-OA as defined by the DC/TMDs, and RCTs assessing the treatment outcomes of i-PRF in patients with limited MMO were included. Studies without control or comparative arm, retrospective studies, narrative reviews, and animal studies were excluded.
Two reviewers (M.B.M and N.M.H) independently assessed the eligibility of the retrieved electronic titles and abstracts, then evaluated the potentially relevant full-text articles. Subsequently, data was extracted from the selected eligible articles. The agreement between both reviewers was appraised by the Cohen’s Kappa coefficient. Disagreements in the assessments in study selection and data extraction were settled by direct discussion among reviewers. Qualitative data analysis was conducted by applying descriptive methods.
Meta-analysis
Meta-analysis was done using Meta-Analysis Online (https://metaanalysisonline.com/). The heterogeneity of the included studies was judged using I2 values and Q-test. Forest plots with random-effects models were used in the current study due to the high degree of heterogeneity encountered across all outcomes. The estimates were pooled using inverse variance random-effects model and demonstrated as standardized mean difference (SMD) and 95% confidence intervals (CIs). A p-value of less than 0.05 was deemed statistically significant.
Risk of bias
Appraisal of the RCTs was done with the Cochrane Collaboration’s tool for assessing risk of bias [39].
Results
The systematic search identified 137 studies from PubMed, 134 articles from Google Scholar, and 3 studies from the Cochrane library. Of the 274 screened articles and after duplicate removal, the full texts of 12 articles were assessed, and only 6 articles [25–30] were considered eligible as they fulfilled the inclusion criteria. Thus, they were included for data extraction (Fig. 1). Excluded articles with reasons are listed in Table 1.
Fig. 1.
PRISMA Flow Chart for identification and selection of eligible studies
Table 1.
Excluded studies
A total of 270 subjects participated in the studies reviewed. In five studies [25–27, 29, 30], the gender of patients was identified (201 females, 55 males). In all the included studies [25–30], sample selection was not gender-based, with an interesting finding in Işik et al. study [27] where only 3 participants were males. Four studies [25–27, 29, 30] identified the age range of the participants. However, one study [28] did not identify the age range but mentioned that the average age in each study group. Demographic data are presented in Table 2.
Table 2.
Demographic data of the included studies
| Author/Year | Sample size | Female No. (%) | Male No. (%) | Age Range (years) |
|---|---|---|---|---|
| Karadayi et al. 2021 [25] | 36 |
19 (53%) (i-PRF group:10; Control group:9) |
17 (47%) (i-PRF group: 8; Control group:9) |
20–64 (mean age = 39.82) |
| Ghoneim et al. 2022 [26] | 40 |
29(72.5%) (i-PRF group:16; Control group:13) |
11(27.5%) (i-PRF group:4; Control group:7) |
18–55 (i-PRF group: 44.67 ± 12.13; control group: 45.72 ± 13.12) |
| Işik et al. 2022 [27] | 36 |
33(92%) (i-PRF group:16; Control group:17) |
3(8%) (i-PRF group:2; Control group:1) |
≥ 18 (i-PRF group: 44.67 ± 12.13; control group: 45.72 ± 13.12) |
| Sharma et al. 2023 [28] | 14 | Not identified | Not identified | 20–50 |
| Işik et al. 2023 [29] | 76 |
69(90.8%) (i-PRF group:34; Control group:35) |
7(9.2%) (i-PRF group:4; Control group:3) |
≥ 18 (i-PRF group: 47.2 ± 9.1; control group: 46.8 ± 10.2) |
| Kumar et al. 2024 [30] | 68 |
51(75%) (i-PRF group:25; Control group:26) |
17(25%) (i-PRF group:9; Control group:8) |
18–60 (i-PRF group: 42.5 ± 8.2; control group: 41.8 ± 7.5) |
| Total |
270 256 (with gender identified) |
201 (78.5 %) | 55 (21.5%) |
All the included studies [25–30] investigated the effectiveness of i-PRF on joint pain and MMO. All studies [25–30] used Visual Analogue Scale (VAS) to assess pain. One study [25] applied Helkimo clinical dysfunction scoring and TMJ clicking was assessed in two studies [25, 27]. Four studies [25–29] noted the effect of i-PRF on the lateral excursions while three studies [27–29] evaluated its effect on the protrusive movements as well. Only one study [28] evaluated the disc position and joint effusion on MRI after the treatment. A synopsis of the characteristics of the studies reviewed is provided in Table 3, and findings of the studies on TMD pain, MMO, and reported side effects are grouped in Table 4. Furthermore, this meta-analysis assessed the effects of i-PRF on various TMJ outcomes involving pain, MMO, protrusive, and lateral movements.
Table 3.
Summary of the characteristics of the included studies
| Author/Year | Sample size | TMDs | i-PRF group | control/comparative group(s) | Injection Site(s) | Use of US |
Injection Vol./Freq. | Follow-up periods | Outcomes |
|---|---|---|---|---|---|---|---|---|---|
| Karadayi et al. 2021 [25] | 36 |
TMJ-ID (Wilkes stage > 3) |
Arthrocentesis + i-PRF (n = 18) |
Arthrocentesis (Lactated Ringer solution) (n = 18) | Superior joint space | No | 2 ml/one time |
Day 0,10,30,90 |
VAS (0–10) Helkimo Clinical Dysfunction Score MMO |
| Ghoneim et al. 2022 [26] | 40 |
TMJ-ID (DDr) |
Arthrocentesis + i-PRF (n = 20) |
Arthrocentesis (Lactated Ringer solution) (n = 20) | Superior joint space | No | 1.5 ml/one time |
Week 0,7,21,24 |
VAS (0–10) Clicking MMO, lateral excursions (mm) |
| Işik et al. 2022 [27] | 36 | TMJ-OA |
Arthrocentesis + i-PRF (n = 18) |
Arthrocentesis (saline solution) (n = 18) | Superior joint space | No | 1 ml/4 times (0,1,2,3w) |
Month 0,1,2,3,6,12 |
VAS (0–10) MMO, lateral & protrusive movements (mm) |
| Sharma et al. 2023 [28] | 14 |
TMJ-ID (Wilkes stage 1–4) |
Arthrocentesis (Lactated Ringer solution) + i-PRF (n = 7) |
Arthrocentesis (Lactated Ringer solution) + PRP (n = 7) |
Superior joint space | No |
2 ml/6 times (0,1,2,3,4,5 m) |
Month 0,1,2,3,4,5,6,9 |
VAS (0–10) MMO, lateral & protrusive movements (mm) Joint sounds MRI (Disc position, JE) |
| Işik et al. 2023 [29] | 76 |
TMJ-ID (DDWor) |
Arthrocentesis + i-PRF (n = 38) |
Arthrocentesis (saline solution) (n = 38) | Superior joint space | No | 1 ml/4 times (0,1,2,3w) |
Month 0,1,2,3,6,12 |
VAS (0–10) MMO, lateral & protrusive movements (mm) |
| Kumar et al. 2024 [30] | 68 |
Unspecified (TMJ pain) |
i-PRF (n = 38) |
No active treatment (n = 38) |
Superior joint space | No |
1 ml/twice (0,1 w) |
Week 0,6,12,24 |
VAS (0–10) MMO (mm) PROs QoL (Questionnaires) |
TMDs Temporomandibular Disorders, TMJ-ID Temporomandibular Joint Internal Derangement, TMJ-OA Temporomandibular Joint Osteoarthritis, DDr Reducible Disc Displacement, i-PRF Injectable Platelet Rich Fibrin, PRP Platelet Rich Plasma, DDWor Disc Displacement without reduction, US Ultrasound, w weeks, VAS Visual Analog Scale, MMO Maximum Mouth Opening, PROs QoL Patient-Reported Outcomes on Quality of Life and Satisfaction
Table 4.
Findings of the included studies on TMD pain, MMO, and reported side effects
| Author/Year | Effect on TMD Pain | Effect on MMO | Other Findings | Side Effects | Conclusions |
|---|---|---|---|---|---|
| Karadayi et al. 2021 [25] |
٠ The mean VAS scores after 30 days showed a statistically significantly lower mean score compared to baseline (p < 0.001). ٠ Difference between groups was statistically significant at the follow-ups. |
٠ The mean MMO after 1 m & 3 m showed statistically significantly higher mean value than baseline in both groups. ٠ After 30 days, there was a statistically significant difference between both groups, where i-PRF group showed higher MMO than the control group. ٠ At 3 m, no statistically significant difference was noted between both groups. |
٠ After 10 days, an insignificant decrease in HCDS was noted in each group. However, the difference between both groups was statistically significant. ٠ There was a statistically significant decrease in HCDS after 30 days with statistically significant difference between the 2 groups. |
None |
٠ The use of i-PRF with arthrocentesis showed better results than arthrocentesis alone. ٠ Multiple PRF injections might be applied for severe TMDs. |
| Ghoneim et al. 2022 [26] |
٠ Within each group, a significant relief of pain was noted at the follow-ups. ٠ There was a statistically significant difference (p < 0.001) between the two groups along the evaluation periods. |
٠ After 1 w, the MMO was significantly increased in both groups (p = 0.032). However, the i-PRF group showed higher values than the control group. ٠ Arthrocentesis + i-PRF outperformed arthrocentesis alone with a statistically significant difference (p < 0.05). |
٠ TMJ clicking was assessed showing a statistically significant difference (p < 0.05) between both groups at the follow-up periods. ٠ Statistically significant differences between clicking scores within each group was noted. ٠ In the i-PRF group, TMJ clicking disappeared in 75% of the patients after 7 days post injection (p < 0.001). ٠ The measurements of lateral movements showed a statistically significant increase within each group over time. The difference between both groups was statistically significant. |
In the i-PRF group, 2 patients showed transient inability to occlude in maximum intercuspation in the 1st 48 h post- injection. |
٠ Additional i-PRF injections after arthrocentesis are of more effectiveness than arthrocentesis alone in the management of TMJ-ID. ٠ The intracapsular injection of i-PRF is a low-risk method with promising outcomes regarding relief of pain, TMJ clicking & improving range of mandibular movements. |
| Işik et al. 2022 [27] |
٠ A decrease in pain levels was noted in both groups, with a statistically significant difference. ٠ A significant increase in pain levels was observed only in the control group from the 6th to 12th m (p < 0.001). Difference between groups was statistically significant at follow-up periods. |
٠ In the i-PRF group, the MMO increased postoperatively, and this improvement was maintained up to the 12th m. ٠ Difference between groups was statistically significant during follow-up periods, where the i-PRF group showed higher values than the control group. ٠ A significant decrease in MMO was noted in the control group from the 6th to 12th m postoperatively (p < 0.001). |
٠ In the i-PRF group, there was an increase in the range of lateral and protrusive movements up to 12 m with a statistically significant differences at the 1 st and 2nd m postoperatively (p < 0.001), and no significant differences from the 2nd to the 12th m. ٠ As for functional jaw movements, the difference between both groups was statistically significant. ٠ The range of excursive movements in the i-PRF group were significantly higher than that in the control group during follow-up periods. ٠ The range of lateral and protrusive movements decreased significantly in the control group from the 6th to 12th m postoperatively (p < 0.001) |
None | Intracapsular injection of i-PRF after arthrocentesis should be preferred as it reduces pain levels & improves jaw movements up to 12 m. |
| Sharma et al. 2023 [28] |
٠ The mean of VAS score showed a statistically significant difference between both groups at 1 week after the 1st injection and 1 week after the 2nd injection. While at 1 week after the 3rd, 4th, 5th, and 6th injections and at the 9th month follow–up, no statistical difference (p = 0.450, 0.805, 0.338, 0.509, and 0.509, respectively) was found. ٠ In the i-PRF group, no statistically significant reduction was noted for 1st and 2nd follow up followed by a significant reduction till 9 months (p < 0.001). |
٠ The intragroup comparison of MMO from baseline to various follow up revealed that in PRP group and i-PRF group II statistically significant change was found in the 1st month (p = 0.015 and p = 0.008 respectively). ٠ A statistically significant difference was observed between the groups 3rd injection onward (p < 0.001). |
٠ Both groups demonstrated statistically significant results where i-PRF group showed better results as compared to PRP group regarding the improvement of lateral and protrusive movement.٠ A significant disappearance in TMJ clicking was noted in patients 2 weeks posttreatment and was sustained through the follow-ups. However, no statistically significant difference was noted in the presence of joint sound between the groups. ٠ Disc position, on MRI, had improved toward normal with significant changes in both groups at the 9 month follow up; however, the i-PRF group showed better results. ٠ At the 9 month follow up, the joint effusion was significantly less in both groups |
None | i PRF has showed better results regarding the efficacy over PRP across all assessed parameters. |
| Işik et al. 2023 [29] |
٠ Pain on palpation, chewing, and jaw movements decreased significantly on the 1st m postoperatively in both groups. ٠ A significant increase in pain levels was observed only in the control group from the 6th to 12th m (p < 0.001). ٠ Difference between groups was statistically significant at follow-up periods(p < 0.001). |
٠ A statistically significant increase in the degree of MMO was noted at the 1st, 2nd, 3rd, and 6th m postoperatively, when compared to preoperative measurements for each group. ٠ The increase in MMO was preserved up to the 12th m in the i-PRF group while a significant decrease in MMO was noted in the control group from the 6th to 12th m postoperatively (p < 0.001). ٠ Difference between groups was statistically significant, where the i-PRF group showed higher values than the control group. |
٠ In the i-PRF group, there was an increase in the measurements of contralateral, ipsilateral, and protrusive movements up to 12m with a statistically significant difference at the 1st and 2nd m postoperatively (p < 0.001), and no significant differences from the 2nd to the 12th m. ٠ The measurements of contralateral, ipsilateral, and protrusive movements in the i-PRF group were significantly higher than that in the control group during follow-up periods. ٠ Significant decreases in measurements of jaw movements were noted in the control group from the 6th to 12th m postoperatively (p < 0.001). |
None | i-PRF used with arthrocentesis is an effective adjunctive management for DDWor as it relieves clinical symptoms. |
| Kumar et al. 2024 [30] | ٠ Through the follow-ups, the i-PRF group showed a noteworthy reduction in TMJ pain intensity compared to the control group that was statistically significant. (p < 0.001). | ٠ At all the follow-ups, a substantial improvement in MMO within the i-PRF group was noted compared to controls (p<0.001). | ٠ A notable increase in PROs QoL in the i-PRF group was observed compared to controls (p<0.001) in which the patients receiving i-PRF reported improvements in their overall well-being and treatment satisfaction. | None | i-PRF showed significant efficacy in relieving TMJ pain, improving MMO, and enhancing the patients’ quality of life. |
VAS Visual analogue Scale, MMO Maximum Mouth Opening, m months, i-PRF Injectable Platelet Rich Fibrin, HCDS Helkimo clinical dysfunction score, m months, h hours, TMJ Temporomandibular Joint, TMJ-ID Temporomandibular Joint Internal Derangement
i-PRF Preparation protocol
In all studies [25–30], Choukroun et al. [36] protocol was utilized to prepare i-PRF where un-coated tubes without additives were used for blood collection and then centrifuged at a low speed (700 rpm) for three minutes.
i-PRF injection protocol and site
In all the included studies [25–30], injections were done under local anesthesia. However, Karadayi et al. [25] and Sharma et al. [28] performed auriculotemporal nerve block while in Ghoneim et al. [26] study, local anesthesia was infiltrated into the joint. In both studies by Işık et al. [27, 29], the exact technique for administration of LA was not mentioned.
Regarding the injection of i-PRF, ultrasound-guided injection was not applied in all the included studies [25–30]. However, skin anatomic landmarks were used to identify the site of injection; the superior joint compartment, where i-PRF was injected 1 cm in front of the tragus and 2 mm beneath the canthus-tragus line.
In 5 studies [25–29], the injection of i-PRF was accompanied by arthrocentesis; however, in one study [30] arthrocentesis was not performed.
i-PRF injection volume and frequency
Different volumes of i-PRF were used in the included studies where it ranged from 1 ml to 2 ml. In Karadayi et al. [25] study and Sharma et al. [28] study, 2 ml were injected while Işik et al. [26, 29] and Kumar et al. [30] utilized 1 ml per injection. Ghoneim et al. [26] administrated 1.5 ml of i-PRF. Single i-PRF injection was performed in 2 studies [25, 26], i-PRF was injected twice in one study [30], while 4 injections were applied in 2 studies [27, 29], and 6 injections were administered in one study [28].
i-PRF effect on TMJ pain
Six studies [25–30] evaluated changes in pain using the Visual Analogue Scale (VAS). Meta-analysis demonstrated that i-PRF resulted in a significantly greater reduction in pain compared with control interventions (pooled SMD = − 2.16; 95% CI = − 3.73 to − 0.59; P = 0.007). Notably, Işik et al. [27, 29] reported that, only in the control group, pain levels increased significantly from the 6th month to the 12th month. Considerable heterogeneity was observed among studies (I² = 86%), reflecting differences in patient selection, injection frequency, and follow-up duration. (Fig. 2).
Fig. 2.
Forest plot for the i-PRF effect on TMJ pain
i-PRF effect on MMO
Six studies [25–30] assessed improvements in MMO following treatment. Ghoneim et al. [26] reported a positive effect on MMO in both the i-PRF group and the control group. However, the i-PRF group showed higher values of MMO than that in the control group. Similar effect on MMO was observed by Karadayi et al. [25], and Işik et al. [27, 29] where i-PRF outperformed the other interventions used. Nevertheless, Karadayi et al. [25] found that in 3 months, the difference between the i-PRF group and the control group was negligible. In Kumar et al. [30] study, the authors documented a significant improvement in the i-PRF group compared to the control group who received no active treatment. Pooled analysis showed a significant mean increase of 2.46 mm in the i-PRF group compared with controls (95% CI = 0.56 to 4.36; P = 0.02). Considerable heterogeneity was also noted among studies (I² = 93%) (Fig. 3).
Fig. 3.
Forest plot for the i-PRF effect on MMO
i-PRF effect on protrusive & lateral mandibular movements
Four studies [25–29] noted the effect of i-PRF on lateral excursions while 3 studies [27–29] evaluated its effect on protrusive movements as well. In 2 studies by Işik et al. [27, 29], there was an increase in the range of protrusive and lateral movements over the 12 months of follow-up with a statistically significant difference at the 1 st and the 2nd month postoperatively. However, no significant difference was noted from the 2nd till the 12th month postoperatively. Furthermore, in the control group, the range of excursive movements decreased significantly from the 6th to 12th month.
Ghoneim et al. [26] reported a statistically significant increase in the measurements of lateral movements within each group over time where the difference between both groups was statistically significant.
The pooled meta-analysis demonstrated a moderate overall effect favoring i-PRF for lateral movements (SMD = 1.35; 95% CI = 0.03 to 2.67; P = 0.048; I² = 83%), indicating substantial heterogeneity among studies (Fig. 4). For protrusive movements, the pooled effect was not statistically significant (SMD = 1.76; 95% CI = − 0.97 to 4.48; P = 0.11; I² = 89%), suggesting that improvements were inconsistent across trials. These findings indicate that i-PRF may contribute to short-term improvement in lateral mandibular movement, while its effect on protrusive movement remains uncertain due to inter-study variability and small sample sizes (Fig. 5).
Fig. 4.
Forest plot for the i-PRF effect on lateral mandibular movements
Fig. 5.
Forest plot for the i-PRF effect on protrusive mandibular movements
i-PRF effect on TMJ sounds
Three studies reported [25, 26, 30] on joint clicking or crepitation. Owing to variation in outcome reporting scales, quantitative synthesis was not feasible; however, the qualitative trend suggested symptomatic improvement. Ghoneim et al. [26] found that TMJ clicking ceased in 75% of the patients after 1-week post-injection in the i-PRF group. Moreover, there was a statistically significant reduction in TMJ clicking up to 6 months. In Sharma et al. study [28], TMJ clicking was present in 71.4% of the joints, in the i-PRF group, pre-injection. In the same study, a significant disappearance in TMJ clicking was noted in 2 weeks posttreatment and after 1 month from the first injection, clicking was found only in 35.7% and by the 5th month, no clicking was noted in all patients.
In U. Karadayi and B. Gursoytrak study [25], the Helkimo clinical dysfunction scoring was used where it includes joint sounds as a clinical criterion. However, no specific results on joint sounds were mentioned.
i-PRF effect on disc position
Only one study [28] assessed the disc position on magnetic resonance imaging (MRI) where the authors found that disc position had improved toward normal with significant changes in both groups at the 9-month follow up; however, the i-PRF group showed better results.
i-PRF effect on joint effusion
One study [28] addressed joint effusion in which it was found that the joint effusion was significantly less at the 9-month follow-up.
Follow-up intervals
Five studies [26–30] out of the 6 included studies were long-term ones; in which Işik et al. studies [27, 29] had a 12-month follow-up period, Sharma et al. study [28] had a 9-month follow up, while Ghoneim et al. [26], and Kumar et al. [30] had a 6-month follow-up.
Reported side effects
Five studies [25, 27–30] reported no adverse effects after i-PRF injections. However, in one study by Ghoneim et al. [26], two patients experienced transient inability to occlude in maximum intercuspation in the first 2 days after i-PRF injection.
Risk of bias within studies
The risk of bias within studies, in compliance with the Cochrane Collaboration’s tool for assessing risk of bias, is shown in Fig. 6. The bias due to blinding was the most common throughout the studies.
Fig. 6.
The risk of bias within studies
Discussion
Since it was introduced a decade ago, i-PRF has proved to have several advantages over PRP in the field of regenerative medicine [32–38]. Based on the beneficial effects of the i-PRF, it has gained attention as an intra-articular agent to treat intracapsular TMD. The current systematic review and meta-analysis aims to focus on the clinical evidence on the effects of the intra-articular injection of i-PRF for the management of patients suffering from either TMJ-ID or TMJ-OA.
This systematic review revealed promising results on the effectiveness of i-PRF in improving MMO, relief of pain as well as reducing joint clicking. Furthermore, in their retrospective short-term study, Torul et al. [22] stated that i-PRF after arthrocentesis led to reduction in pain scores and improvements in MMO and turned out to be of more effectiveness than arthrocentesis alone or with hyaluronic acid (HA). Similar findings were documented by Yuce E and Komerik N [23] in their cohort study. Moreover, Vingender et al. [31] stated that PC as i-PRF and RRP should be preferred as an intra-articular agent for the management of TMD.
In all the included RCTs [25–30], the injection of i-PRF in the superior joint compartment showed better results than the comparative treatment regarding pain levels, and MMO. These results go in accordance with Al-Delayme et al. [14], Torul et al. [22], Yuce et al. [23], Manafikhi et al. [24], and Vingender et al. [31] who reported similar effects of PC derivatives on TMD symptoms and MMO. Furthermore, Sharma et al. [28] reported noticeable changes toward the normal articular disc position with reduction in the joint effusion where the authors mentioned an improvement in the disc position in both study groups where PRP and i-PRF were injected in joints with disc displacement with reduction and without reduction as well. Similar effect was noted by Khallaf et al. [18] after the injection of PRP, another form of PC, where they mentioned a significant change towards the normal disc position. These promising findings may be due to the intra-articular regenerative injections into the joint spaces that enhance the micro-environment within the joint leading to the relief of TMD symptoms in a short period as well as prevention of further progression of the ID condition. Moreover, regenerative injections inhibit inflammatory biomarkers, produce more collagen fibrils, widen the joint space, and shift the disc mobility range owing to the in-situ growth factors [13, 32–38].
Sharma et al. [28] reported that clicking was found in five cases out of 7 patients after the 1 st injection of i-PRF while it was reduced to four after the 2nd injection then one (7.1%) at 3rd and 4th injection. By the 5th injection of i-PRF, no joint clicking was noted. This goes in agreement with Manafikhi et al. [24] prospective single-arm clinical study where they found that the clicking ceased in 70% of the patients after 1 week from receiving the 1 st injection of i-PRF, and in all the patients after 1 week from the 2nd injection. However, they reported that clicking returned to two of the patients after 6-month from the 1 st injection. On the other hand, Sharma et al. [28] found that clicking did not return up to the 9-month follow up. Moreover, this might be attributed to the improvement in the disc position reported by the same authors.
Ultrasound-guided intra-articular injections have been used in the past years, making the procedure safe and anticipated with minimum side effects [14, 17, 40–42]. Although all the intra-articular injections in the RCTs included in the present review were not guided by ultrasound, the treatment was effective with no major side effects. Only one study [26] reported a side effect where two patients experienced transient inability to occlude in maximum intercuspation in the first 48 h after the i-PRF injection. This might be contributed to the clotting of the liquid PRF.
The strengths of our systematic review include addressing a topic that has gained attention in regenerative medicine and the research field of TMDs with promising results. In addition to carrying out a meticulous methodology that integrates scientifically based research. However, there are some limitations such as the lack of blinding in most studies which introduces a risk of bias, and that a small number of RCTs were included owing to the lack of RCTs in literature addressing i-PRF effect on TMJ pain and joint dysfunction related to TMJ-ID and TMJ-OA. Moreover, the heterogeneity in the patient baseline characteristics, injection protocols, control groups, follow-up duration, assessment methods, and the fact that only one study [28] assessed disc position and joint effusion on MRI, limiting mechanistic insights pose as further shortcomings of the current review. Nevertheless, these limitations highlight the need for further long-term RCTs with standardized i-PRF preparation and injection protocols that may employ the use of ultrasound-guided intra-articular injections.
Conclusion
Promising results were found on the effect of i-PRF in the management of TMJ pain and joint dysfunction related to TMJ-ID and TMJ-OA. However, more RCTs are needed to further investigate its beneficial effects.
Acknowledgements
Not Applicable.
Abbreviations
- i-PRF
injectable Platelet Rich Fibrin
- TMJ-ID
Temporomandibular Joint Internal Derangement
- TMJ-OA
Temporomandibular Joint Osteoarthritis
- PICO
Population, Intervention, Comparison, Outcome
- RCTs
Randomized Clinical Trials
- MMO
Maximum Mouth Opening
- TMDs
Temporomandibular Disorders
- TMJ
Temporomandibular Joint
- SMD
Standardized Mean Difference (SMD)
- PC
Platelet Concentrates
- PRP
Platelet-Rich Plasma
- MeSH
Medical Subject Headings
- VAS
Visual Analogue Scale
- HCDS
Helkimo Clinical Dysfunction Score
Authors’ contributions
All authors gathered the data and wrote the manuscript draft. All the authors reviewed and approved this final version of the manuscript.
Funding
Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).
Data availability
All the dataset interpreted during the present review and meta-analysis are obtainable from the corresponding author upon rational request.
Declarations
Ethics approval and consent to participate
Not Applicable.
Consent for publication
Not Applicable.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.McNeill C. Management of temporomandibular disorders: concepts and controversies. J Prosthet Dent. 1997;77(5):510–22. [DOI] [PubMed] [Google Scholar]
- 2.De Leeuw R. Internal derangements of the temporomandibular joint. Oral Maxillofac Surg Clin North Am. 2008;20(2):159–68. [DOI] [PubMed] [Google Scholar]
- 3.Schiffman E, Ohrbach R, Truelove E, et al. Diagnostic criteria for temporomandibular disorders (DC/TMD) for clinical and research applications: recommendations of the international RDC/TMD consortium network and orofacial pain special interest group. J Oral Facial Pain Headache. 2014;28(1):6–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Minervini G, D’Amico C, Cicciù M, Fiorillo L. Temporomandibular joint disk displacement: etiology, diagnosis, imaging, and therapeutic approaches. J Craniofac Surg. 2023;34(3):1115–21. [DOI] [PubMed] [Google Scholar]
- 5.Cardoneanu A, Macovei LA, Burlui AM, Mihai IR, Bratoiu I, Rezus II, Richter P, Tamba BI, Rezus E. Temporomandibular joint osteoarthritis: pathogenic mechanisms involving the cartilage and subchondral bone, and potential therapeutic strategies for joint regeneration. Int J Mol Sci. 2022;24(1):171. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Conti PC, Corrêa AS, Lauris JR, Stuginski-Barbosa J. Management of painful temporomandibular joint clicking with different intraoral devices and counseling: a controlled study. J Appl Oral Sci. 2015;23(5):529–35. 10.1590/1678-775720140438. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Rady NA, Bahgat MM, Abdel-Hamid AM. Promising minimally invasive treatment modalities for symptomatic temporomandibular joint disc displacement with reduction: a randomized controlled clinical trial. BMC Oral Health. 2022;22(1):547. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Hosgor H, Bas B, Celenk C. A comparison of the outcomes of four minimally invasive treatment methods for anterior disc displacement of the temporomandibular joint. Int J Oral Maxillofac Surg. 2017;46(11):1403–10. 10.1016/j.ijom.2017.05.010. [DOI] [PubMed] [Google Scholar]
- 9.Wu CB, Sun NN, Zhang D, Wang Q, Zhou Q. Efficacy analysis of splint combined with platelet-rich plasma in the treatment of temporomandibular joint osteoarthritis. Front Pharmacol. 2022;13:996668. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Rodhen RM, de Holanda TA, Barbon FJ, de Oliveira da Rosa WL, Boscato N. Invasive surgical procedures for the management of internal derangement of the temporomandibular joint: A systematic review and meta-analysis regarding the effects on pain and jaw mobility. Clin Oral Investig. 2022 Mar;15:1–8. [DOI] [PubMed]
- 11.Guarda-Nardini L, De Almeida AM, Manfredini D. Arthrocentesis of the temporomandibular joint: systematic review and clinical implications of research findings. J Oral Facial Pain Headache. 2021;35(1). [DOI] [PubMed]
- 12.Murakami K. Current role of arthrocentesis, arthroscopy and open surgery for temporomandibular joint internal derangement with inflammatory/degenerative disease;-pitfalls and pearls. J Oral Maxillofac Surg Med Pathol. 2022;34(1):1–1. [Google Scholar]
- 13.Al-Hamed FS, Hijazi A, Gao Q, Badran Z, Tamimi F. Platelet concentrate treatments for temporomandibular disorders: a systematic review and meta-analysis. JDR Clin Trans Res. 2021;6(2):174–83. [DOI] [PubMed] [Google Scholar]
- 14.Al-Delayme RE, Alnuamy SH, Hamid FT, Azzamily TJ, Ismaeel SA, Sammir R, Hadeel M, Nabeel J, Shwan R, Alfalahi SJ, Yasin A. The efficacy of platelets rich plasma injection in the superior joint space of the tempromandibular joint guided by ultrasound in patients with non-reducing disk displacement. J Oral Maxillofac Surg. 2017;16(1):43–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Jonathan Albilia DM, Herrera-Vizcaíno C, Choukroun J, Shahram Ghanaati MD. Liquid platelet-rich fibrin injections as a treatment adjunct for painful temporomandibular joints: preliminary results. CRANIO®. 2020;38(5):292–304. 10.1080/08869634.2018.1516183. [DOI] [PubMed] [Google Scholar]
- 16.González LV, López JP, Díaz-Báez D, Orjuela MP, Chavez M. Clinical outcomes of operative arthroscopy and temporomandibular medical infiltration with platelet-rich fibrin in upper and lower articular space. J Cranio Maxill Surg. 2021;49(12):1162–8. [DOI] [PubMed] [Google Scholar]
- 17.Bahgat MM, EL-Helw NR, Abdelhamid AM, Fata MM, Ashour MS, Atteya A. Intra-articular regenerative injection for management of painful irreducible temporomandibular disc displacement. Alex dent j. 2024 Apr 18.
- 18.Khallaf MG, Sidebottom AJ, farouk Elrawy H, Elmasry MS. Evaluation of platelet- rich plasma effect on treatment of temporomandibular joint anterior disc displacement. Am J Oral Maxillofac Surg. 2019;6:14–26. [Google Scholar]
- 19.Haigler MC, Abdulrehman E, Siddappa S, Kishore R, Padilla M, Enciso R. Use of platelet-rich plasma, platelet-rich growth factor with arthrocentesis or arthroscopy to treat temporomandibular joint osteoarthritis: systematic review with meta-analyses. J Am Dent Assoc. 2018;149(11):940–52. [DOI] [PubMed] [Google Scholar]
- 20.Hançı M, Karamese M, Tosun Z, Aktan TM, Duman S, Savaci N. Intra-articular platelet rich plasma injection for the treatment of temporomandibular disorders and a comparison with arthrocentesis. J Craniomaxillofac Surg. 2015;43(1):162–6. [DOI] [PubMed] [Google Scholar]
- 21.Lin SL, Tsai CC, Wu SL, Ko SY, Chiang WF, Yang JW. Effect of arthrocentesis plus platelet-rich plasma and platelet-rich plasma alone in the treatment of temporomandibular joint osteoarthritis: A retrospective matched cohort study (A STROBE-compliant article). Medicine. 2018;97(16):e0477. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Torul D, Cezairli B, Kahveci K. The efficacy of intra-articular injectable platelet-rich fibrin application in the management of Wilkes stage III temporomandibular joint internal derangement. Int J Oral Maxillofac Surg. 2021;50(11):1485–90. [DOI] [PubMed] [Google Scholar]
- 23.Yuce E, Komerik N. Comparison of the efficiacy of intra-articular injection of liquid platelet-rich fibrin and hyaluronic acid after in conjunction with arthrocentesis for the treatment of internal temporomandibular joint derangements. J Craniofac Surg. 2020;31(7):1870–4. [DOI] [PubMed] [Google Scholar]
- 24.Manafikhi M, Ataya J, Heshmeh O. Evaluation of the efficacy of platelet rich fibrin (I-PRF) intra-articular injections in the management of internal derangements of temporomandibular joints–a controlled preliminary prospective clinical study. BMC Musculoskel Dis. 2022;23(1):454. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Karadayi U, Gursoytrak B. Randomised controlled trial of arthrocentesis with or without PRF for internal derangement of the TMJ. J Cranio Maxill Surg. 2021;49(5):362–7. [DOI] [PubMed] [Google Scholar]
- 26.Ghoneim NI, Mansour NA, Elmaghraby SA, Abdelsameaa SE. Treatment of temporomandibular joint disc displacement using arthrocentesis combined with injectable platelet rich fibrin versus arthrocentesis alone. J Dent Sci. 2022;17(1):468–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Işık G, Kenç S, Koyuncu BÖ, Günbay S, Günbay T. Injectable platelet-rich fibrin as treatment for temporomandibular joint osteoarthritis: a randomized controlled clinical trial. J Cranio Maxill Surg. 2022;50(7):576–82. [DOI] [PubMed] [Google Scholar]
- 28.Sharma P, Aurora JK, Dubey KN, Tandon P, Tiwari S. A comparative analysis between intra articular injections of injectable platelet rich fibrin versus platelet rich plasma in the management of temporomandibular disorders: A randomized control trial. Natl J Maxillofac Surg. 2023;14:249–55. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Işık G, Kenç S, Koyuncu BÖ, Günbay S, Günbay T. Does the use of injectable platelet-rich fibrin after arthrocentesis for disc displacement without reduction improve clinical outcomes? JOMS. 2023;81(6):689–97. [DOI] [PubMed] [Google Scholar]
- 30.Kumar N, Francis M, Vk SS, Ramachandra V, Anilkumar PV, Khan MF. Efficacy of injectable Platelet-Rich fibrin (I-PRF) in managing temporomandibular joint pain: A prospective clinical study. Cureus. 2024;16(2). [DOI] [PMC free article] [PubMed]
- 31.Vingender S, Dőri F, Schmidt P, Hermann P, Vaszilkó MT. Evaluation of the efficiency of hyaluronic acid, PRP and I-PRF intra-articular injections in the treatment of internal derangement of the temporomandibular joint: A prospective study. J Cranio Maxill Surg. 2023;51(1):1–6. [DOI] [PubMed] [Google Scholar]
- 32.Miron RJ, Gruber R, Farshidfar N, Sculean A, Zhang Y. Ten years of injectable platelet-rich fibrin. Periodontol 2000. 2024;94(1):92–113. [DOI] [PubMed] [Google Scholar]
- 33.Lee HM, Shen EC, Shen JT, Fu E, Chiu HC, Hsia YJ. Tensile strength, growth factor content and proliferation activities for two platelet concentrates of platelet-rich fibrin and concentrated growth factor. J Dent Sci. 2020;15(2):141–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma:growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85(6):638–46. [DOI] [PubMed] [Google Scholar]
- 35.Choukroun J, Adda F, Schoeffler C, Vervelle A. Une opportunite´ en paro-implantologie: le PRF. Implantodontie. 2000;42:55–62.
- 36.Choukroun J, Ghanaati S. Reduction of relative centrifugation force within injectable platelet-rich-fibrin (PRF) concentrateadvances patients’ own inflammatory cells, platelets and growth factors: the first introduction to the low-speed centrifugation concept. Eur J Trauma Emerg Surg. 2018;44:87–95. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Abd El Raouf M, Wang X, Miusi S, et al. Injectable-platelet rich fibrin using the low-speed centrifugation concept improves cartilage regeneration when compared to platelet-rich plasma. Platelets. 2019;30:213–21. [DOI] [PubMed] [Google Scholar]
- 38.Chai J, Jin R, Yuan G, Kanter V, Miron RJ, Zhang Y. Effect of liquid platelet-rich fibrin and platelet-rich plasma on the regenerative potential of dental pulp cells cultured under inflammatory conditions: a comparative analysis. J Endod. 2019;45:1000–8. [DOI] [PubMed] [Google Scholar]
- 39.Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Parra DA, Chan M, Krishnamurthy G, Spiegel L, Amaral JG, Temple MJ, John PR, Connolly BL. Use and accuracy of US guidance for image-guided injections of the temporomandibular joints in children with arthritis. Pediatr Radiol. 2010;40:1498–504. [DOI] [PubMed] [Google Scholar]
- 41.Orhan K, Rozylo-Kalinowska I. Ultrasonography-Guided invasive procedures of the temporomandibular joint. Clin Dent Rev. 2021;5(1):3. [Google Scholar]
- 42.Cha YH, Park JK, Yang HM, Kim SH. Ultrasound-guided versus blind temporomandibular joint injections: a pilot cadaveric evaluation. Int J Oral Maxillofac Surg. 2019;48(4):540–5. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All the dataset interpreted during the present review and meta-analysis are obtainable from the corresponding author upon rational request.